Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer

Jiang, W; He, ZC; Zhang, TT; Guo, CC; Zhao, JL; Zhu, JH; Wu, JY; Yu, XX; Chen, CX; Li, JF; Jiang, J

Wu, JY; Yu, XX (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pharm, Guangzhou 510030, Peoples R China.; Jiang, J (corresponding author), Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China.; Jiang, J (corresponding author), Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Chinese Minist Educ MOE, Guangzhou 510632, Peoples R China.; Jiang, J (corresponding author), Jinan Univ, Dongguan Inst, Dongguan 523808, Peoples R China.

IMMUNOTHERAPY, 2021; 13 (8): 661

Abstract

Aim: To evaluate the cost-effectiveness of ribociclib plus fulvestrant versus fulvestrant in hormone receptor-positive/human EGF receptor 2-negative a......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索